{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:03:40Z","timestamp":1787695420446,"version":"build-2784847793"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals U.S.A., Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical indices to characterize the severity of inflammatory bowel disease (IBD) are widely used in clinical trials and real-world practice. However, there are few validated instruments for assessing IBD severity in administrative claims-based studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients (18\u201389 years) diagnosed with ulcerative colitis (UC) or Crohn\u2019s disease (CD) and receiving \u22651 prescription claim for IBD therapy were identified using administrative claims data from the Optum Clinformatics, IMS PharMetrics, and Truven MarketScan databases (January 1, 2013\u2013September 30, 2017). Regression modeling identified independent predictors of IBD-related hospitalization (inpatient stay or emergency department visit resulting in hospitalization), which were used to develop IBD severity indices. The index was validated against all-cause hospitalization and total cost and IBD-related hospitalization and total cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 51,767 patients diagnosed with UC (n = 30,993) or CD (n = 20,774) who were initiated treatment with IBD therapy. Independent predictors of IBD-related hospitalization were Charlson Comorbidity Index score &amp;gt;1, anemia, weight loss, intravenous corticosteroid use, prior gastrointestinal-related emergency department visit and hospitalization, and unspecified disease location or more extensive disease. Female sex, renal comorbidities, intestinal fistula, and stricture were additional risk factors for patients with CD, whereas age &amp;lt;40 years was a UC-specific risk factor. Median IBD severity scores were 8 and 13 for UC and CD, respectively, from possible total scores of 51 and 37. Inflammatory bowel disease severity score correlated with significantly higher all-cause hospitalization and cost, all-cause total cost, IBD-related hospitalization cost, and total cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These validated UC and CD severity indices can be used to predict IBD-related outcomes using administrative claims databases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaa263","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T06:25:03Z","timestamp":1602483903000},"page":"1177-1183","source":"Crossref","is-referenced-by-count":20,"title":["Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study"],"prefix":"10.1093","volume":"27","author":[{"given":"Grace","family":"Chen","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc. , Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Lissoos","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc. , Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dieyi","sequence":"additional","affiliation":[{"name":"STATinMED Research , Plano, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle D","family":"Null","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc. , Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"2023112501054536800_CIT0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet."},{"key":"2023112501054536800_CIT0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"key":"2023112501054536800_CIT0003","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet."},{"key":"2023112501054536800_CIT0004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"GBD 2017 Inflammatory Bowel Disease Collaborators","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2023112501054536800_CIT0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1590\/1414-431x20143774","article-title":"Classical and recent advances in the treatment of inflammatory bowel diseases","volume":"48","author":"Sales-Campos","year":"2015","journal-title":"Braz J Med Biol Res."},{"key":"2023112501054536800_CIT0006","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1093\/jcag\/gwy050","article-title":"The impact of inflammatory bowel disease in Canada 2018: indirect costs of IBD care","volume":"2","author":"Kuenzig","year":"2019","journal-title":"J Can Assoc Gastroenterol."},{"key":"2023112501054536800_CIT0007","doi-asserted-by":"crossref","first-page":"e0142481","DOI":"10.1371\/journal.pone.0142481","article-title":"Evolution of costs of inflammatory bowel disease over two years of follow-up","volume":"11","author":"van der Valk","year":"2016","journal-title":"PLoS One."},{"key":"2023112501054536800_CIT0008","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ecco-jcc\/jjz003","article-title":"The Evolution of health care utilisation and costs for inflammatory bowel disease over ten years","volume":"13","author":"Pillai","year":"2019","journal-title":"J Crohns Colitis."},{"key":"2023112501054536800_CIT0009","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112501054536800_CIT0010","first-page":"2460","article-title":"Systematic review of the clinical disease severity indices for inflammatory bowel disease","volume":"21","author":"Alrubaiy","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2023112501054536800_CIT0011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/flgastro-2014-100530","article-title":"Development and validation of a new disease severity index: the Inflammatory Bowel Disease Index (IBDEX)","volume":"6","author":"Alrubaiy","year":"2015","journal-title":"Frontline Gastroenterol."},{"key":"2023112501054536800_CIT0012","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"Siegel","year":"2018","journal-title":"Gut."},{"key":"2023112501054536800_CIT0013","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther."},{"key":"2023112501054536800_CIT0014","first-page":"46958019887816","article-title":"Identifying patients with inflammatory bowel diseases in an administrative health claims database: do algorithms generate similar findings?","volume":"56","author":"Ye","year":"2019","journal-title":"Inquiry."},{"key":"2023112501054536800_CIT0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10408340500526766","article-title":"The correlation coefficient: an overview","volume":"36","author":"Asuero","year":"2006","journal-title":"Crit Rev Anal Chem."},{"key":"2023112501054536800_CIT0016","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s12325-019-01095-1","article-title":"Analysis of safety, medical resource utilization, and treatment costs by drug class for management of inflammatory bowel disease in the United States based on insurance claims data","volume":"36","author":"Long","year":"2019","journal-title":"Adv Ther."},{"key":"2023112501054536800_CIT0017","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4292\/wjgpt.v7.i2.235","article-title":"Predictive factors for a severe clinical course in ulcerative colitis: results from population-based studies","volume":"7","author":"Wander\u00e5s","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"2023112501054536800_CIT0018","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/ajg.2010.105","article-title":"A novel risk score to stratify severity of Crohn\u2019s disease hospitalizations","volume":"105","author":"Ananthakrishnan","year":"2010","journal-title":"Am J Gastroenterol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/8\/1177\/53788375\/izaa263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/8\/1177\/53788375\/izaa263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T20:06:15Z","timestamp":1700856375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/27\/8\/1177\/5920980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,10,12]]},"published-print":{"date-parts":[[2021,7,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa263","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2020,10,12]]}}}